Chemotherapy With Eribulin Following Potentially Curative Surgery in Patients With Localized Liposarcoma

Area of Science:

• Oncology
• Pharmacology

Background:

• Soft tissue sarcomas, including liposarcoma (LPS), are rare and aggressive cancers with high recurrence rates.
• Eribulin is approved for metastatic LPS after prior chemotherapy, but its use as adjuvant therapy post-surgery is not well-documented.

Purpose of the Study:

• To evaluate the efficacy and tolerability of adjuvant eribulin in patients with high-risk liposarcoma (LPS) unsuitable for intensive chemotherapy.
• To assess eribulin's potential as a postoperative treatment following surgical resection.

Main Methods:

• A retrospective, single-center analysis was conducted.
• Efficacy and safety of eribulin were evaluated in five high-risk LPS patients who received it post-surgery.

Main Results:

• Five patients with LPS received adjuvant eribulin after surgical resection.
• Median progression-free survival was 12.3 months, and median overall survival was 44.3 months.
• Eribulin demonstrated manageable toxicity, with rare severe (grade 3+) adverse events.

Conclusions:

• Postoperative eribulin may be a feasible treatment option for select high-risk LPS patients who are not candidates for intensive chemotherapy.
• Further prospective clinical trials are necessary to confirm these findings and establish eribulin's role in adjuvant LPS treatment.